PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27034723-3	2016	Mirodenafil, a second-generation PDE5I, has biochemical profiles such as high affinity for PDE5 and high selectivity for PDE5 over other PDE isoforms, compared to other existing PDE5Is such as sildenafil, vardenafil and tadalafil.	mirodenafil	0-11	phosphodiesterase 5A	Homo sapiens	33-37	
27034723-3	2016	Mirodenafil, a second-generation PDE5I, has biochemical profiles such as high affinity for PDE5 and high selectivity for PDE5 over other PDE isoforms, compared to other existing PDE5Is such as sildenafil, vardenafil and tadalafil.	mirodenafil	0-11	phosphodiesterase 5A	Homo sapiens	91-95	
27034723-3	2016	Mirodenafil, a second-generation PDE5I, has biochemical profiles such as high affinity for PDE5 and high selectivity for PDE5 over other PDE isoforms, compared to other existing PDE5Is such as sildenafil, vardenafil and tadalafil.	mirodenafil	0-11	phosphodiesterase 5A	Homo sapiens	91-95	
20626604-1	2010	INTRODUCTION: Mirodenafil is a newly developed selective phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED).	mirodenafil	14-25	phosphodiesterase 5A	Homo sapiens	57-81	
24872948-3	2014	Mirodenafil is a newly developed pyrrolopyrimidinone compound, which is a potent, reversible, and selective oral PDE5 inhibitor.	mirodenafil	0-11	phosphodiesterase 5A	Homo sapiens	113-117	
21460862-7	2011	We found reports on five kinds of PDE-5 inhibitors for the management of ED: sildenafil, vardenafil, tadalafil, udenafil and mirodenafil.	mirodenafil	125-136	phosphodiesterase 5A	Homo sapiens	34-39	
21585174-7	2011	Among the other PDE5 inhibitors under development we report mirodenafil, lodenafil carbonate, avalafil and SLx-2101 It is likely that in the future molecules that act on pathways other than the one of NO/cGMP will be available.	mirodenafil	60-71	phosphodiesterase 5A	Homo sapiens	16-20	
20626604-1	2010	INTRODUCTION: Mirodenafil is a newly developed selective phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED).	mirodenafil	14-25	phosphodiesterase 5A	Homo sapiens	83-87	
19695390-1	2009	BACKGROUND: Mirodenafil is a phosphodiesterase type 5 (PDE-5) inhibitor developed for the treatment of erectile dysfunction.	mirodenafil	12-23	phosphodiesterase 5A	Homo sapiens	29-53	
19695390-1	2009	BACKGROUND: Mirodenafil is a phosphodiesterase type 5 (PDE-5) inhibitor developed for the treatment of erectile dysfunction.	mirodenafil	12-23	phosphodiesterase 5A	Homo sapiens	55-60	
18197727-5	2008	In addition, several new PDE5 inhibitors are candidates to enter the market in forthcoming years (avanafil, udenafil, SLx-2101, mirodenafil [SK3530]).	mirodenafil	128-139	phosphodiesterase 5A	Homo sapiens	25-29